<DOC>
	<DOCNO>NCT02554890</DOCNO>
	<brief_summary>The purpose study assess effect in-hospital initiation sacubitril/valsartan ( LCZ696 ) vs. enalapril time average proportional change NT-proBNP patient stabilize follow hospitalization acute decompensated heart failure ( ADHF ) reduce ejection fraction ( left ventricular ejection fraction ( LVEF ) ≤ 40 % ) .</brief_summary>
	<brief_title>comParIson Of Sacubitril/valsartaN Versus Enalapril Effect ntpRo-bnp Patients Stabilized From Acute Heart Failure Episode</brief_title>
	<detailed_description />
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Enalapril</mesh_term>
	<mesh_term>Enalaprilat</mesh_term>
	<mesh_term>Valsartan</mesh_term>
	<mesh_term>LCZ 696</mesh_term>
	<criteria>Key 1 . Possess capacity provide write informed consent must obtain assessment perform . 2 . Currently hospitalize ADHF . Patients diagnosis acute heart failure symptom sign fluid overload ( i.e . jugular venous distention , edema rale auscultation pulmonary congestion chest xray ) time hospitalization . 3 . Eligible patient randomize earlier 24 hour ten day presentation still hospitalize long meet following definition stable status : SBP ≥100mm Hg precede 6 hour prior randomization ; symptomatic hypotension No increase ( intensification ) i.v . diuretic dose within last 6 hour prior randomization No i.v . inotropic drug 24 hour prior randomization No i.v . vasodilator include nitrate within last 6 hour prior randomization 4 . LVEF ≤40 % within past 6 month ( include current hospitalization ) use echocardiography , multi gated acquisition scan ( MUGA ) , CT scanning , MRI ventricular angiography , provide subsequent study document EF &gt; 40 % . 5 . Elevated NTproBNP ≥ 1600pg/mL OR BNP ≥400 pg/mL current hospitalization . Key 1 . Currently take sacubitril/valsartan tablet use within past 30 day . 2 . Enrollment clinical trial involve investigational agent investigational device . 3 . History hypersensitivity , know suspected contraindication , intolerance study drug , include ACEIs , ARBs , Sacubitril ( NEP inhibitor ) . 4 . Patients known history angioedema relate previous ACE inhibitor ARB therapy . 5 . Requirement treatment ACE inhibitor ARB . 6. eGFR &lt; 30 ml/min/1.73 m2 measure simplified Modification Diet Renal Disease ( MDRD ) formula screen . 7 . Serum potassium &gt; 5.2 mEq/L screening . 8 . Known hepatic impairment ( evidenced total bilirubin &gt; 3 mg/dL , increase ammonia level , perform ) , history cirrhosis evidence portal hypertension varix 9 . Acute coronary syndrome , stroke , transient ischemic attack ; cardiac , carotid major CV surgery ; percutaneous coronary intervention ( PCI ) carotid angioplasty , within one month prior Visit 1 . 10 . Pregnant nursing ( lactate ) woman , pregnancy define state female conception termination gestation , confirm positive hCG laboratory test . 11 . Women childbearing potential , defined woman physiologically capable become pregnant , include woman whose career , lifestyle , sexual orientation precludes intercourse male partner woman whose partner sterilize vasectomy mean , UNLESS use two birth control method .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Acute</keyword>
	<keyword>Heart Failure</keyword>
	<keyword>reduce ejection fraction</keyword>
	<keyword>NTproBNP</keyword>
	<keyword>Heart failure reduce ejection fraction ( HFREF )</keyword>
</DOC>